Hatchtech board and management changes
22-Apr-2009
- Australia
Since joining Hatchtech in 2005, Dr MacLeman and the board, management and advisors, have moved the company from research to Phase II human trials of the single treatment head lice control product DeOvo™. This is a new generation low-toxicity lousicide that is expected to be the first highly effective treatment for human head lice.
Dr MacLeman will continue with Hatchtech until the end of April.
Most read news
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.